You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,093,206


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,093,206
Title:Methods involving long lasting synthetic exendin-4 peptide conjugates
Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
Inventor(s): Bridon; Dominique P. (San Francisco, CA), L\'Archeveque; Benoit (Dorval, CA), Holmes; Darren L. (Anaheim, CA), Leblanc; Anouk (Montreal, CA), St. Pierre; Serge (Ile Bezard, CA)
Assignee: Conjuchem, LLC (Los Angeles, CA)
Application Number:11/304,446
Patent Claims:1. A method for treating obesity in a subject, comprising administering to the subject a therapeutically effective amount of a compound according to the following formula: ##STR00018##

2. The method of claim 1, wherein said compound is in association with a physiologically acceptable medium.

3. A method for treating obesity in a subject, comprising administering to the subject a therapeutically effective amount of a conjugate formed by reacting a compound according to the following formula: ##STR00019## with albumin, wherein said reacting forms a covalent bond between said compound and albumin.

4. The method of claim 3, wherein said albumin is serum albumin.

5. The method of claim 3, wherein said reacting occurs between said compound and cysteine 34 thiol of albumin.

6. The method of claim 3, wherein said conjugate is in association with a physiologically acceptable medium.

7. The method of claim 4, wherein said conjugate is in association with a physiologically acceptable medium.

8. The method of claim 5, wherein said conjugate is in association with a physiologically acceptable medium.

9. A method for treating decreased insulin sensitivity in a subject, comprising administering to the subject a therapeutically effective amount of a compound according to the following formula: ##STR00020##

10. The method of claim 9, wherein said compound is in association with a physiologically acceptable medium.

11. A method for treating decreased insulin sensitivity in a subject, comprising administering to the subject a therapeutically effective amount of a conjugate formed by reacting a compound according to the following formula: ##STR00021## with albumin, wherein said reacting forms a covalent bond between said compound and albumin.

12. The method of claim 11, wherein said albumin is serum albumin.

13. The method of claim 11, wherein said reacting occurs said compound and cysteine 34 thiol of albumin.

14. The method of claim 11, wherein said conjugate is in association with a physiologically acceptable medium.

15. The method of claim 12, wherein said conjugate is in association with a physiologically acceptable medium.

16. The method of claim 13, wherein said conjugate is in association with a physiologically acceptable medium.

17. The method of any one of claims 1-8, wherein the subject is a human.

18. The method of any one of claims 9-16, wherein the subject is a human.

19. The method of claim 4, wherein the serum albumin is human serum albumin.

20. The method of claim 5, wherein said albumin is serum albumin.

21. The method of claim 20, wherein said conjugate is in association with a physiologically acceptable medium.

22. The method of claim 21, wherein the subject is a human.

23. The method of claim 5, wherein said albumin is human serum albumin.

24. The method of claim 23, wherein said conjugate is in association with a physiologically acceptable medium.

25. The method of claim 24, wherein the subject is a human.

26. The method of claim 12, wherein the serum albumin is human serum albumin.

27. The method of claim 13, wherein said albumin is serum albumin.

28. The method of claim 27, wherein said conjugate is in association with a physiologically acceptable medium.

29. The method of claim 28, wherein the subject is a human.

30. The method of claim 13, wherein said albumin is human serum albumin.

31. The method of claim 30, wherein said conjugate is in association with a physiologically acceptable medium.

32. The method of claim 31, wherein the subject is a human.

Details for Patent 8,093,206

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 10/21/1942 ⤷  Try a Trial 2019-05-17
Baxalta Us Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 03/03/1954 ⤷  Try a Trial 2019-05-17
Csl Behring Ag ALBURX albumin (human) Injection 102366 07/23/1976 ⤷  Try a Trial 2019-05-17
Grifols Biologicals Llc ALBUTEIN albumin (human) Injection 102478 08/15/1978 ⤷  Try a Trial 2019-05-17
Instituto Grifols, S.a. HUMAN ALBUMIN GRIFOLS albumin (human) Injection 103352 02/17/1995 ⤷  Try a Trial 2019-05-17
Instituto Grifols, S.a. HUMAN ALBUMIN GRIFOLS albumin (human) Injection 103352 06/11/2003 ⤷  Try a Trial 2019-05-17
Csl Behring Llc ALBUMINAR, ALBUMINAR-20, ALBUMINAR-25, ALBUMINAR-5 albumin (human) Injection 103955 03/17/2000 ⤷  Try a Trial 2019-05-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.